Middle East respiratory syndrome coronavirus infection natural history, complications and prognosis: Difference between revisions
Joao Silva (talk | contribs) No edit summary |
Joao Silva (talk | contribs) |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
To date, the mortality rate of MERS-CoV is approximately 30%. | [[MERS|Middle East Respiratory Syndrome]] ([[MERS]]) is a [[viral]] [[respiratory disease|respiratory illness]]. It is caused by an emerging [[coronavirus]], specifically a ''betacoronavirus'' called [[Middle east respiratory syndrome coronavirus|MERS-CoV]] ([[Middle east respiratory syndrome coronavirus|Middle East Respiratory Syndrome Coronavirus]]), first discovered in 2012. Being a relatively novel [[virus]], there is no [[virus]]-specific [[prevention]] or treatment options for [[MERS]] patients. Attending to the fact that a [[vaccine]] hasn't been developed yet, enhancing [[infection]] prevention and control measures is critical to prevent the possible spread of [[MERS-CoV]] in hospitals and communities. | ||
To date, the [[mortality rate]] of [[MERS-CoV]] is approximately 30%. Cases have been reported where critically ill patients have developed complications such as: [[acute renal failure]], [[pericarditis]] and [[disseminated intravascular coagulation ]].<ref name="pmid23782859">{{cite journal| author=Drosten C, Seilmaier M, Corman VM, Hartmann W, Scheible G, Sack S et al.| title=Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. | journal=Lancet Infect Dis | year= 2013 | volume= 13 | issue= 9 | pages= 745-51 | pmid=23782859 | doi=10.1016/S1473-3099(13)70154-3 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23782859 }} </ref><ref name="pmid24841273">{{cite journal| author=Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J et al.| title=Repurposing of clinically developed drugs for treatment of Middle East Respiratory Coronavirus Infection. | journal=Antimicrob Agents Chemother | year= 2014 | volume= | issue= | pages= | pmid=24841273 | doi=10.1128/AAC.03036-14 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24841273 }} </ref><ref name=WHO>{{cite web | title = Clinical management of severe acute respiratory infections when novel coronavirus is suspected: What to do and what not to do | url = http://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCoronavirus_11Feb13u.pdf }}</ref><ref name=CDC>{{cite web | title = MERS Prevention and Treatment | url = http://www.cdc.gov/coronavirus/MERS/about/prevention.html }}</ref> | |||
==Complications== | ==Complications== | ||
Revision as of 14:01, 23 June 2014
|
Middle East Respiratory Syndrome Coronavirus Infection Microchapters |
|
Differentiating Middle East Respiratory Syndrome Coronavirus Infection from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Middle East respiratory syndrome coronavirus infection natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Middle East respiratory syndrome coronavirus infection natural history, complications and prognosis |
|
Directions to Hospitals Treating Middle East respiratory syndrome coronavirus infection |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Middle East Respiratory Syndrome (MERS) is a viral respiratory illness. It is caused by an emerging coronavirus, specifically a betacoronavirus called MERS-CoV (Middle East Respiratory Syndrome Coronavirus), first discovered in 2012. Being a relatively novel virus, there is no virus-specific prevention or treatment options for MERS patients. Attending to the fact that a vaccine hasn't been developed yet, enhancing infection prevention and control measures is critical to prevent the possible spread of MERS-CoV in hospitals and communities. To date, the mortality rate of MERS-CoV is approximately 30%. Cases have been reported where critically ill patients have developed complications such as: acute renal failure, pericarditis and disseminated intravascular coagulation .[1][2][3][4]
Complications
Prognosis
References
- ↑ Drosten C, Seilmaier M, Corman VM, Hartmann W, Scheible G, Sack S; et al. (2013). "Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection". Lancet Infect Dis. 13 (9): 745–51. doi:10.1016/S1473-3099(13)70154-3. PMID 23782859.
- ↑ Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J; et al. (2014). "Repurposing of clinically developed drugs for treatment of Middle East Respiratory Coronavirus Infection". Antimicrob Agents Chemother. doi:10.1128/AAC.03036-14. PMID 24841273.
- ↑ "Clinical management of severe acute respiratory infections when novel coronavirus is suspected: What to do and what not to do" (PDF).
- ↑ "MERS Prevention and Treatment".